These findings reveal a potential role of aPL antibodies in potentiating thrombosis in hospitalized patients with COVID-19 through promotion of NET formation and highlight aPL antibodies and NET formation as appealing therapeutic targets. The gene discussed is FASLG; the disease is COVID-19.